ERYTECH aktualisiert Informationen zur prüfarztgesponserten Phase-II-Studie von Eryaspase als Zweitlinientherapie bei akuter lymphoblastischer Leukämie

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement